196 related articles for article (PubMed ID: 17047650)
1. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
Alain T; Kim M; Johnston RN; Urbanski S; Kossakowska AE; Forsyth PA; Lee PW
Br J Cancer; 2006 Oct; 95(8):1020-7. PubMed ID: 17047650
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
[TBL] [Abstract][Full Text] [Related]
4. Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64.
Baer GS; Dermody TS
J Virol; 1997 Jul; 71(7):4921-8. PubMed ID: 9188554
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
Samson A; Bentham MJ; Scott K; Nuovo G; Bloy A; Appleton E; Adair RA; Dave R; Peckham-Cooper A; Toogood G; Nagamori S; Coffey M; Vile R; Harrington K; Selby P; Errington-Mais F; Melcher A; Griffin S
Gut; 2018 Mar; 67(3):562-573. PubMed ID: 27902444
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
7. Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.
Mohamed A; Teicher C; Haefliger S; Shmulevitz M
J Virol; 2015 Apr; 89(8):4319-34. PubMed ID: 25653434
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins C; Simpson GR; Rogers W; Relph K; Harrington K; Melcher A; Roulstone V; Kyula J; Pandha H
Cancer Gene Ther; 2018 Jun; 25(5-6):148-160. PubMed ID: 29720674
[TBL] [Abstract][Full Text] [Related]
12. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.
Campion CA; Soden D; Forde PF
BMC Cancer; 2016 Jul; 16():462. PubMed ID: 27412241
[TBL] [Abstract][Full Text] [Related]
13. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus.
Kennedy BE; Murphy JP; Clements DR; Konda P; Holay N; Kim Y; Pathak GP; Giacomantonio MA; Hiani YE; Gujar S
Cancer Res; 2019 Aug; 79(15):3824-3836. PubMed ID: 31088833
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression promotes reovirus therapy of colorectal liver metastases.
Smakman N; van der Bilt JD; van den Wollenberg DJ; Hoeben RC; Borel Rinkes IH; Kranenburg O
Cancer Gene Ther; 2006 Aug; 13(8):815-8. PubMed ID: 16543920
[TBL] [Abstract][Full Text] [Related]
19. Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells.
Dautzenberg IJC; van den Hengel SK; de Vrij J; Ravesloot L; Cramer SJ; Hong SS; van den Wollenberg DJM; Boulanger P; Hoeben RC
Sci Rep; 2017 Dec; 7(1):17654. PubMed ID: 29247249
[TBL] [Abstract][Full Text] [Related]
20. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
